« Return to News | Awards & Advancement

Quintiles named best CRO in vaccine excellence awards

Friday, April 13, 2012 02:01 PM

Quintiles, a global biopharmaceutical services company, has been named “Best Clinical Research Organization” (CRO) in the Vaccine Industry Excellence (ViE) Awards 2012, which recognizes and celebrates the leaders, innovators and pioneers in the vaccines industry.

“This is a great honor to be recognized as the “Best CRO” at the World Vaccine Congress,” said Dr. Ellen Vigdorth, VP Allergy, Respiratory, Infectious Diseases and Vaccines. “It is a huge achievement and underscores our commitment to the development of quality vaccines and anti-infective products.

Customers voted for their preferred CRO prior to the World Vaccine Congress; a judging panel then made its selection based on the following criteria: 1) Range of services provided in niche and core therapeutic areas; 2) Methods of performance improvement or introduction of new services; 3) Attention to and quality of relationships with clients; 4) Reaching of milestones and final/ongoing outcomes; 5) Building and maintaining existing and long-term partnerships.

This award comes shortly after Quintiles was named, for the second year running, the 2012 “Asia Pacific CRO of the Year” at the BioPharma Convention Awards.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.